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Introduction
Tumor necrosis factor receptor associated periodic syn-
drome (TRAPS) is a multifaceted auto inflammatory
syndrome which was initially described in persons of
Irish-Scottish ancestry and in ethnic groups of northern
European descent. To date, more than 70 mutations
have been described. Since then, it has been described
in other ethnicities. There have been few reports of
from Asia, 11 cases have been described from Japan,
and only one case of TRAPS has been described in an
Arab child from Israel (1-8).There are no cases of
TRAPS that have been described from Gulf Arab states.
Objectives
We hereby report 2 sisters with homozygous R92Q var-
iant in the TNFRSF1 gene of Arabic origins from Oman
with different clinical course, one which also had the
E148Q mutation in MEFV gene.
Methods
Detailed clinical description of two sisters including
their family pedigree along with their laboratory investi-
gations including measurement of TNF-a in both
patients and their parents, in addition to sequencing of
TNFRSF1A and MEFV.
Results
12 yrs old girl presented at 18 months of age with epi-
sodes of high fever, lasting for 5 to 7 days occurring at
monthly intervals. The attacks were associated with
abdominal pain, vomiting, myalgias, arthralgia with
occasional chest pains. Investigations during febrile epi-
sodes revealed anemia, leukocytosis, thrombocytosis and
elevated inflammatory markers. Infectious, immunologi-
cal, rheumatological and malignancy work up was nega-
tive. Sequencing of the MEFV gene revealed a
heterozygous c.442G>C (E148Q) mutation resulting in
the diagnosis of Familial Mediterranean Fever. She
responded to colchicine for 4 years and to etanercpet
for 2 years. Revision of the diagnosis was necessary due
to change in clinical symptoms. The duration of fever
was lasting up to 10-14 days with the occurrence of
occasional periorbital swelling and redness. TRAPS was
considered, and sequencing of the TNFRSF1A gene
revealed homozygous R92Q variants. She was treated
with anakinra with sustained dramatic clinical improve-
ment for more than 12 months.
6 yrs old sister, presented at the age of 18 months with
similar clinical episodes, but less severe in intensity and
frequency. She had no significant clinical response to col-
chicines and showed transient response to etanercept
lasting 3 months. She was also found to have homozy-
gous R92Q variants in the TNFRSF1A gene. Anakinra
was started with dramatic clinical improvement.
Conclusion
R92Q is a nonstructural gene mutation with low disease
penetrance resulting in a mild disease course in patients
with TRAPS (9). We present 2 sisters with homozygous
R92Q mutation presenting with different clinical disease
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course, a moderate and severe course which is unusual.
In patients with atypical clinical features, an overlapping
gene syndrome should be considered as in patient 1
who presented with a severe protracted clinical course
not responding to conventional therapy. Perhaps the
overlapping genes explain the difference in disease
course. However, this postulation would contradict pre-
vious studies that found that the interaction between





1Child Health, Sultan Qaboos University Hospital, Muscat, Oman. 2Child
Health, Royal Hospital, Muscat, Oman. 3Genetics, Sultan Qaboos University
Hospital, Muscat, Oman.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P225
Cite this article as: Abdwani et al.: PReS-FINAL-2235: Overlap of
homozygous TNFRSF1A R92Q mutation with MEVF E148Q mutation
versus homozygous TNFRSF1A R92Q mutation: difference in clinical
profile in two sisters from Oman. Pediatric Rheumatology 2013 11
(Suppl 2):P225.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Abdwani et al. Pediatric Rheumatology 2013, 11(Suppl 2):P225
http://www.ped-rheum.com/content/11/S2/P225
Page 2 of 2
